isoniazid has been researched along with rifapentine in 181 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.10) | 18.7374 |
| 1990's | 6 (3.31) | 18.2507 |
| 2000's | 24 (13.26) | 29.6817 |
| 2010's | 88 (48.62) | 24.3611 |
| 2020's | 61 (33.70) | 2.80 |
| Authors | Studies |
|---|---|
| Bitting, C; Gruppo, V; Johnson, CM; Lenaerts, AJ; Marietta, KS; Orme, IM; Woolhiser, L | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bismuth, R; Grosset, J; Lecoeur, H; Truffot-Pernot, C | 1 |
| Arioli, V; Berti, M; Carniti, G; Randisi, E; Rossi, E; Scotti, R | 1 |
| Chapuis, L; Grosset, JH; Ji, B; O'Brien, RJ; Raviglione, MC; Truffot-Pernot, C | 1 |
| He, GJ | 1 |
| Chan, SL; Kam, KM; Lam, CW; Leung, CC; Mitchison, DA; Morris, JS; Tam, CM | 1 |
| Benator, D; Bozeman, L; Burman, W; Khan, A; Vernon, A | 1 |
| Bishai, WR; Chaisson, RE; Miyazaki, E | 1 |
| Chase, SE; Chmielewski, AJ; Cynamon, MH; Lenaerts, AM | 1 |
| Al-Ghusein, H; Chan, SL; Kam, KM; Mitchison, DA; Sim, E; Sole, KM; Staples, D; Tam, CM | 1 |
| Daniel, N; Geiter, LJ; Grosset, J; Hejblum, G; Ji, B; Lounis, N; O'Brien, RJ; Szpytma, M; Truffot-Pernot, C; Vernon, A | 1 |
| Arnadottir, T; Enarson, DA; Rieder, HL; Trébucq, A | 1 |
| Bentoucha, A; Grosset, J; Ji, B; Lounis, N; O'Brien, RJ; Roscigno, G; Truffot-Pernot, C; Vernon, A | 1 |
| Burman, W; Horsburgh, CR; Vernon, A | 1 |
| Chan, SL; Goodall, RL; Kam, KM; Mitchison, DA; Tam, CM | 1 |
| Bock, NN; Conwell, DS; Hamilton, CD; Mosher, A; Pachucki, C; Samuels, M; Sterling, TR; Vernon, A; Wang, YC | 1 |
| Benator, D; Bhattacharya, M; Bozeman, L; Burman, W; Cantazaro, A; Chaisson, R; Gordin, F; Horsburgh, CR; Horton, J; Khan, A; Lahart, C; Metchock, B; Pachucki, C; Stanton, L; Vernon, A; Villarino, ME; Wang, YC; Weiner, M; Weis, S | 1 |
| Au-Yeang, C; Chan, CY; Cheng, AF; Leung, CC; Yew, WW | 1 |
| Bock, N; Burman, WJ; Goldberg, S; Hayden, K; Khan, A; Peloquin, CA; Sterling, TR; Vernon, A; Weiner, M; Weis, S; Zhao, Z | 1 |
| Gordin, FM | 1 |
| Bozeman, L; Burman, WJ; Cave, MD; Jasmer, RM; Khan, A; Metchock, B; Saukkonen, JJ; Schwartzman, K | 1 |
| Donald, PR; Langdon, G; Maritz, JS; Sirgel, FA; Smith, PJ; Venter, A | 1 |
| Barnes, GL; Chaisson, RE; Coberly, JS; Falco, G; Faulhaber, JC; Moore, RD; Schechter, M; Zajdenverg, R | 1 |
| Bishai, WR; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, K | 1 |
| Bhutani, H; Prasad, B; Singh, S | 1 |
| Burman, WJ | 1 |
| Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, KN; Zhang, M | 1 |
| Cáceres, N; Cardona, PJ; Gil, O; Guirado, E; Singh, M; Vilaplana, C | 1 |
| Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M | 1 |
| Sterling, TR | 1 |
| Belknap, R; Kestler, M; Reves, R | 1 |
| Hamilton, CD; Holland, DP; Sanders, GD; Stout, JE | 2 |
| Lange, C; Leung, CC; Rieder, HL; Yew, WW | 1 |
| Ahmad, Z; Almeida, DV; Converse, PJ; Grosset, JH; Li, SY; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Zhang, M | 1 |
| Barnes, GL; Chaisson, RE; Gray, GE; Hausler, H; Martinson, NA; McIntyre, JA; Moulton, LH; Msandiwa, R; Ram, M | 1 |
| Churchyard, G; Nardell, E | 1 |
| Bliven-Sizemore, E; Borisov, AS; Bozeman, L; Chaisson, RE; Conde, MB; Gordin, F; Hackman, J; Hamilton, CD; Horsburgh, CR; Kerrigan, A; Menzies, D; Shang, N; Sterling, TR; Villarino, ME; Weiner, M; Weis, SE; Wing, D | 1 |
| Dye, C | 1 |
| Amoabeng, O; Andries, K; Mdluli, KE; Minkowski, A; Nuermberger, EL; Peloquin, CA; Taylor, D; Wallis, RS; Williams, K | 1 |
| Dutta, NK; Grosset, JH; Illei, PB; Karakousis, PC; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Pinn, ML | 1 |
| Person, AK; Sterling, TR | 1 |
| Almeida, D; Grosset, JH; Karakousis, PC; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tasneen, R; Zhang, M | 1 |
| Vernon, A | 1 |
| Kadhiravan, T; Sharma, A; Sharma, SK; Tharyan, P | 1 |
| Parekh, MJ; Schluger, NW | 1 |
| de Castilla, DL; Jain, R; Limaye, AP; Narita, M; Rakita, RM; Spitters, CE | 1 |
| Diel, R; Loddenkemper, R; Migliori, GB; Sotgiu, G | 1 |
| Borisov, AS; Chesson, H; Heilig, CM; Holland, DP; Kerrigan, A; Mac Kenzie, WR; Marks, SM; Scott, N; Shang, N; Shepardson, D; Sterling, TR; Tian, X; Villarino, ME | 1 |
| Abubakar, I; Harris, RJ; Lipman, MC; Muñoz, L; Stagg, HR; Zenner, D | 1 |
| Bateson, AL; Butcher, PD; Charalambous, S; Churchyard, GJ; Clouting, HE; Coleman, D; Geldenhuys, H; Harrison, TS; Hatherill, M; Jindani, A; Magweta, L; McHugh, TD; McIlleron, HM; Mitchison, DA; Mungofa, S; Nunn, AJ; Nyirenda, S; Phillips, PP; Shah, NA; Shepherd, J; van Dijk, JH; Zizhou, S; Zvada, SP | 1 |
| Conde, MB; Goldberg, SV; Jones, B; Moro, RN; Nachman, S; Oliveira, R; Scott, NA; Shang, N; Sterling, TR; Villarino, ME; Weiner, M; Weis, SE | 1 |
| Marais, BJ | 1 |
| Brigden, G; Furin, J; Marais, B; Van Gulik, C | 1 |
| Adkinson, NF; Borisov, AS; Ho, C; Moro, RN; Phillips, E; Shepherd, G; Sterling, TR; Villarino, ME; Weis, S | 1 |
| Bancroft, LW; Engel, AJ; Macke, JJ; Sawin, PD | 1 |
| Chaisson, RE; Getahun, H; Matteelli, A; Raviglione, M | 1 |
| Barnes, GL; Carman, D; Chaisson, RE; Dawson, R; Dorman, SE; Efron, A; Gupte, N; Hoffman, J; McIlleron, H; Narunsky, K; Whitelaw, A | 1 |
| Andersen, JW; Bao, Y; Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Kim, P; Mohapi, L; Mwelase, T; Podany, AT; Supparatpinyo, K; Swindells, S | 1 |
| Benator, D; Bliven-Sizemore, EE; Bock, N; Drobeniuc, J; Reves, R; Schwartzman, K; Shang, N; Sterling, TR; Villarino, ME | 1 |
| Burzynski, JN; Herbert, C; Macaraig, M; Nilsen, D; Stennis, NL | 1 |
| Javid, B; Kong, C; Liu, C; Qian, F; Wu, G; Zhu, J | 1 |
| Abubakar, I; Aziz, MA; Baddeley, A; Barreira, D; Borroto Gutierrez, SM; Bruchfeld, J; Burhan, E; Cavalcante, S; Cedillos, R; Chaisson, R; Chee, CB; Chesire, L; Corbett, E; D Grant, A; Dara, M; de Vries, G; Den Boon, S; Denholm, J; Falzon, D; Ford, N; Gale-Rowe, M; Getahun, H; Gilpin, C; Girardi, E; Go, UY; Govindasamy, D; Grzemska, M; Harris, R; Horsburgh, CR; Ismayilov, A; Jaramillo, E; Kik, S; Kranzer, K; Lienhardt, C; LoBue, P; Lönnroth, K; Marks, G; Matteelli, A; Menzies, D; Migliori, GB; Mosca, D; Mukadi, YD; Mwinga, A; Nelson, L; Nishikiori, N; Oordt-Speets, A; Rangaka, MX; Raviglione, M; Reis, A; Rotz, L; Sandgren, A; Sañé Schepisi, M; Schünemann, HJ; Sharma, SK; Sotgiu, G; Stagg, HR; Sterling, TR; Tayeb, T; Uplekar, M; van der Werf, MJ; van Kessel, F; van't Hoog, A; Vandevelde, W; Varma, JK; Vezhnina, N; Voniatis, C; Vonk Noordegraaf-Schouten, M; Weil, D; Weyer, K; Wilkinson, RJ; Yoshiyama, T; Zellweger, JP | 1 |
| Bleything, S; Hunter, P; Lines, G | 1 |
| Cruz, AT; Martinez, BJ | 1 |
| Cruz, AT; Graviss, EA; Hatzenbuehler, LA; Smith, EO; Starke, JR | 1 |
| Cruz, AT; Starke, JR | 2 |
| Hamilton, CD; Holland, DP; Stout, JE | 1 |
| Armstrong, DT; Barnes, GL; Cavalcante, SC; Chaisson, RE; Cohn, S; Conde, MB; Dalcolmo, M; Dooley, KE; Dorman, SE; Duarte, RS; Durovni, B; Efron, A; Loredo, C; Marzinke, MA; Mello, FC; Moulton, LH; Rolla, V; Savic, RM | 1 |
| Benator, DA; Benson, CA; Calvet, G; Chaisson, RE; Chen, MP; Gordin, F; Infante, R; La Rosa, A; Miro, JM; Scott, NA; Sterling, TR; Villarino, ME | 1 |
| Lu, JM; Sha, W; Xiao, HP; Yang, H; Zhang, LL; Zhang, Q | 1 |
| Abbo, LM; Camargo, JF; Morris, MI; Rosa, R; Simkins, J | 1 |
| Huang, YW; Tsao, SM; Tsao, TC; Yang, SF; Yeh, YP | 1 |
| Abbo, LM; Camargo, JF; Morris, MI; Simkins, J | 1 |
| Dhanireddy, S; Eastment, M; McClintock, AH; McKinney, CM; Molnar, A; Narita, M; Park, DR; Pitney, CL | 1 |
| Reichman, LB | 1 |
| Dhand, A; Knoll, BM; Nog, R; Wu, Y | 1 |
| Alvarez, GG; Hamel, C; Hutton, B; Moher, D; Pease, C; Quach, P; Skidmore, B; Wolfe, D; Yazdi, F | 1 |
| Conyers, A; Dunlay, J; Griffin, P; Holzschuh, EL; Johnson, K; Martin, G; Province, S; Shemwell, C; Showalter, A; Tausz, N; Walls, C | 1 |
| Bamrah-Morris, S; Chorba, T; Griffin, P; Ho, CS; Holcombe, JM; Hunt, G; Jereb, J; Lobato, MN; Marco, A; Marks, S; Mase, S; Moro, RN; Mukasa, L; Nwana, N; Patil, N; Sandul, AL; Shah, N; Stewart, B; Wang, SH; Webb, R | 1 |
| Li, L; Sun, XW; Wang, Z; Xiao, H; Zhang, CL; Zhang, H | 1 |
| Barry Iii, CE; Cole, ST; Dartois, V; Duque-Correa, MA; Gengenbacher, M; Kaiser, P; Kaufmann, SHE; Lazar, D; Makarov, V; Nayyar, A; Reece, ST; Schuerer, S; Zedler, U | 1 |
| Jinbo, J; Kloetzel, M; Lustik, M; West, GF | 1 |
| Arguello Perez, E; Brown, AE; Eisenstein, C; Schneider, WJ; Seo, SK | 1 |
| Horsburgh, CR; Linas, BP; Marks, SM; Salomon, JA; Tasillo, A; Trikalinos, TA | 1 |
| Arevalo, B; Belknap, R; Borisov, AS; Caylà, JA; Chen, MP; Feng, PJ; Holland, D; Martinson, NA; Millet, JP; Miró, JM; Moro, RN; Scott, NA; Villarino, ME; Weiner, M; Wright, A | 1 |
| Biggs, B; Chen, C; Denholm, JT; Eisen, D; Leder, K; Matchett, E; McBryde, ES; Shultz, TR; Street, A | 1 |
| Belknap, RW; Chaisson, RE; Goldberg, SV; Leung, CC; Lopez, M; Machado, ES; Moro, RN; Narita, M; Sanchez, J; Schluger, NW; Schwartzman, K; Scott, NA; Sterling, TR; Tepper, NK; Vernon, A; Villarino, ME | 1 |
| Alfaro, RM; Brooks, KM; De, P; Dobos, KM; George, JM; Hadigan, C; Kellogg, A; Kovacs, JA; Kumar, P; McLaughlin, M; McManus, M; Mehaffy, C; Pau, AK; Rupert, A | 1 |
| Alvarez, GG; Barbeau, P; Hamel, C; Hutton, B; Pease, C; Skidmore, B; Wolfe, D; Yazdi, F | 1 |
| Churchyard, GJ; Dowdy, DW; Johnson, KT; Sohn, H | 1 |
| Chen, DY; Chen, HH; Chen, YM; Liao, TL | 1 |
| Stock, D | 1 |
| Chen, TC; Chen, YH; Chiu, YW; Hsieh, MH; Hwang, SJ; Lin, SY; Lu, PL | 1 |
| Borisov, AS; Moro, RN; Morris, SB; Njie, GJ; Vernon, AA; Woodruff, RY | 1 |
| Allen, L; Bamrah Morris, S; Borisov, AS; Burton, D; Goldberg, S; LoBue, P; Njie, GJ; Vernon, A; Winston, CA; Yelk Woodruff, R | 1 |
| Flexner, C; Moss, DM; Owen, A; Podany, AT; Rajoli, RKR; Siccardi, M; Swindells, S | 1 |
| Chan, PC; Chang, LY; Chuang, YC; Huang, WC; Huang, YW; Ruan, SY; Sun, HY; Wang, JT; Wang, JY | 1 |
| Belknap, RW; Haas, MK | 1 |
| Doan, TN; Fox, GJ; McBryde, ES; Meehan, MT; Ragonnet, R; Scott, N; Trauer, JM; Viney, K | 1 |
| Cao, X; Chen, X; Chen, Y; Cui, W; Feng, B; Gao, L; Guan, L; Guan, X; Jin, Q; Li, H; Li, X; Liu, J; Liu, Z; Ma, Y; Pan, S; Shen, F; Wang, D; Xin, H; Yan, J; Zhang, H; Zhang, Z; Zhou, X | 1 |
| Bruchfeld, J; Fröberg, G; Jansson, L | 1 |
| Andersen, HE; Arnesen, TM; Dyrhol-Riise, AM; Madebo, T; Schein, YL; Tveiten, H; White, RA; Winje, BA | 1 |
| Burzynski, J; Chuck, C; Haque, A; Lam, CK; Macaraig, M; McGinnis Pilote, K | 1 |
| Menzies, D; Trajman, A | 1 |
| Ford, N; Getahun, H; Hamada, Y; Schenkel, K | 1 |
| Chang, AH; Holcombe, M; Lan, E; Marks, SM; Morris, SB; Nwana, N | 1 |
| Andersen, J; Banda, P; Benson, CA; Chaisson, RE; da Silva Escada, RO; Fletcher, CV; Gupta, A; Hakim, J; Jean Juste, MA; Kanyama, C; Lama, JR; Langat, D; Leon-Cruz, J; Masheto, G; Mawlana, S; Mohapi, L; Moran, L; Mwelase, N; Nuermberger, E; Omoz-Oarhe, A; Ramchandani, R; Severe, P; Supparatpinyo, K; Swindells, S; Valencia, J | 1 |
| Evans, CA; Saunders, MJ | 1 |
| Chan, PC; Chen, WW; Chiang, CY; Feng, TY; Huang, YC; Huang, YF; Lee, CC; Lee, PH; Lu, MJ | 1 |
| Barry, PM; Cattamanchi, A; Flood, J; Goodell, AJ; Hill, A; Kahn, JG; Marks, SM; McCabe, D; Porco, TC; Shete, PB; Vreman, R | 1 |
| Basham, CA; Derksen, S; Kinew, KA; Larcombe, L; Lix, LM; McCulloch, S; Plourde, PJ; Schultz, J | 1 |
| Horsburgh, CR; Sterling, TR; Stout, JE | 1 |
| Chaisson, RE; Ramchandani, R; Swindells, S | 1 |
| Altman, J; Blumberg, HM; Bucşan, AN; Day, CL; Doyle, LA; Ernst, JD; Foreman, TW; Gandhi, NR; Kaushal, D; Mehra, S; Peloquin, C; Rengarajan, J; Russell-Lodrigue, K | 1 |
| Arevalo, B; Bessler, P; Borisov, AS; Bozeman, L; Dukes Hamilton, C; Goldberg, SV; Hecker, EJ; Hedges, KNC; Kerrigan, A; Moreno-Martinez, A; Saukkonen, JJ; Scott, NA | 1 |
| Dlodlo, RA; Harries, AD; Kumar, AMV; Satyanarayana, S; Takarinda, KC; Timire, C | 1 |
| Bishai, W; Vernon, A | 1 |
| Cai, L; Huang, X; Jiang, T; Lin, M; Liu, X; Pan, K; Ruan, Q; Shao, L; Shen, Y; Wu, J; Yang, Q; Zhang, W | 1 |
| Chen, WW; Chiou, HL; Huang, WC; Huang, YW; Lin, CH; Tsao, SM; Yang, SF; Yang, WT; Yu, YY | 1 |
| Bachyrycz, A; Borrego, ME; Burgos, M; Ferreira, J; Fortune, D; Jakeman, B; Logothetis, SJ; Roberts, MH | 1 |
| Cao, X; Feng, B; Gao, L; Guan, L; Guan, X; Jin, Q; Li, H; Li, X; Liu, J; Liu, Z; Pan, S; Shen, F; Wang, D; Xin, H; Yan, J; Yang, Q; Zhang, H; Zhang, M | 1 |
| Cao, B; Cui, X; Gao, L | 1 |
| Al Abri, S; Al Khalili, S; Kowada, A; Ndunda, N; Petersen, E; Yaqoubi, F | 1 |
| Ho, CS; Powell, KM; Schmit, KM; Wortham, JM | 1 |
| Mayanja-Kizza, H | 1 |
| Beattie, T; Chaisson, RE; Churchyard, GJ; Dooley, KE; Edward, VA; Fyvie, MJ; Gupte, A; Likoti, M; Marzinke, MA; Savic, R; Sebe, M; Shibambo, I; Wolf, L; Zhang, N | 1 |
| Kraft, WK; Lam, E; Schaefer, J; Zhan, T; Zheng, R | 1 |
| Chen, CY; Feng, JY; Huang, WC; Lee, SS; Li, CP; Lin, CB; Lin, SM; Pan, SW; Shu, CC; Su, WJ; Tung, CL; Wang, TY; Wei, YF | 1 |
| Cai, LM; Hong, JJ; Huang, XT; Jiang, T; Lin, MY; Ling, Q; Liu, XF; Ma, CL; Mao, JC; Pan, KC; Peng, GQ; Ruan, QL; Shao, LY; Shen, YJ; Wang, XD; Wang, XZ; Wu, J; Wu, TZ; Yang, QL; Zhang, WH | 1 |
| Podany, AT | 1 |
| Hesseling, AC; Hibma, JE; Radtke, KK; Savic, RM | 1 |
| Baker, P; Bao, Y; Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Haas, DW; Mohapi, L; Mwelase, N; Podany, AT; Supparatpinyo, K; Swindells, S | 1 |
| Aiona, K; Belknap, RW; Erlandson, KM; Haas, MK | 1 |
| Dowdy, DW; Hill, AN; Marks, SM; Menzies, NA; Parriott, A; Shete, PB; Shrestha, S | 1 |
| Ignatius, EH; Swindells, S | 1 |
| Chaisson, RE; Churchyard, G; Dowdy, D; Ferguson, O; Jo, Y; Johnson, K; Pennington, J | 1 |
| Chen, TC; Cheng, MH; Chong, IW; Huang, CK; Huang, HL; Lai, PC; Lee, MR; Lu, PL; Sheu, CC; Wang, JY | 1 |
| Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Hakim, J; Kanyama, C; Langat, D; Leon-Cruz, J; Mwelase, N; Omoz-Oarhe, A; Podany, AT; Supparatpinyo, K; Swindells, S | 1 |
| Becerra, MC; Hussain, H; Jaswal, M; Keshavjee, S; Khan, AJ; Lu, C; Majidulla, A; Malik, AA; Safdar, N; Yuen, CM | 1 |
| Abubakar, I; Charlett, A; Francis, M; Gosce, L; Hack, V; Kunst, H; Lipman, M; Muñoz, L; Rangaka, MX; Stagg, HR; Surey, J; White, PJ; Yates, TA | 1 |
| Bilek, N; Borate, B; Brumskine, W; Churchyard, G; Erasmus, M; Fiore-Gartland, A; Hadley, K; Hassan-Moosa, R; Hatherill, M; Hiemstra, A; Hikuam, C; Innes, C; Jaxa, L; Kaskar, M; Kimbung Mbandi, S; Malherbe, ST; Mendelsohn, SC; Mulenga, H; Musvosvi, M; Naidoo, K; Penn-Nicholson, A; Raphela, R; Scriba, TJ; Self, S; Sumner, T; Tameris, M; Walzl, G; White, RG | 1 |
| Atuhumuza, E; Cattamanchi, A; Dowdy, D; Kamya, MR; Lim, RK; Muyindike, WR; Namakula-Katende, J; Sabiti, L; Semitala, FC | 1 |
| Amanullah, F; Becerra, MC; Fareed, U; Farooq, S; Hussain, H; Jaswal, M; Keshavjee, S; Khan, AJ; Khan, H; Malik, AA; Nasir, K; Safdar, N; Shahbaz, S | 1 |
| Boyce, C; Huang, FS; Khalil, N; Kohlrieser, CM; Peck, GM; Schlaudecker, EP; Staat, MA | 1 |
| Alvarez, G; Finn, S; Habis, Y; Kilabuk, E; Mallick, R; Mulpuru, S; Patterson, M; Pease, C; Schwartzman, K; Zwerling, A | 1 |
| Hu, ZD; Li, T; Liu, XH; Lu, SH; Ma, JY; Xia, L; Yang, H; Yang, Y; Yu, X | 1 |
| Bradford, S; Britto, P; Chakhtoura, N; Chalermchockcharoentkit, A; Chipato, T; Dooley, KE; Gupta, A; Jayachandran, P; Kamthunzi, P; Langat, D; Mathad, JS; Montepiedra, G; Norman, J; Patil, S; Popson, S; Rouzier, V; Savic, R; Townley, E; Wiesner, L; Zhang, N | 1 |
| Brumskine, W; Cárdenas, V; Chaisson, RE; Charalambous, S; Chihota, V; Churchyard, G; Cobelens, F; Fielding, KL; Garcia-Basteiro, AL; Grant, AD; Martinson, N; Masilela, L; Mngadi, K; Nguenha, D; Sebe, M; van den Hof, S; Waggie, Z; Wang, SH; Yimer, G | 1 |
| Ammerman, NC; Belknap, R; Boyd, R; Ernest, JP; Nuermberger, E; Radtke, KK; Savic, RM; Sterling, TR; Zhang, N | 1 |
| Chang, TE; Huang, YH; Huang, YS; Perng, CL; Tseng, SY | 1 |
| Cheng, CN; Chuang, YC; Hung, CC; Kuo, CH; Lin, KY; Lin, SW; Lin, YJ; Lin, YT; Liou, BH; Liu, WC; Sun, HY | 1 |
| Nolt, D; Starke, JR | 1 |
| Gibbons, S; Khoo, S; Marzolini, C; van Oosterhout, JJ | 1 |
| Akello, L; Belknap, R; Berger, CA; Bishop, O; Cattamanchi, A; Dowdy, DW; Handley, MA; Kadota, JL; Kamya, MR; Katahoire, A; Katamba, A; Kiwanuka, N; Musinguzi, A; Nabunje, J; Nahid, P; Nakitende, A; Patel, D; Phillips, PPJ; Sammann, A; Semitala, FC; Welishe, F | 1 |
| Egorova, A; Makarov, V; Salina, EG | 1 |
| Cheng, MH; Chong, IW; Huang, HL; Huang, SH; Huang, YW; Lee, CH; Lee, JY; Lee, MR; Liu, IH; Lo, YS; Lu, PL; Wang, JY; Yang, JM | 1 |
| Allen, L; Carr, W; Goswami, N; Kurbatova, E; Starks, A; Winston, C | 1 |
| Andia-Biraro, I; Chamba, N; Critchley, JA; Hill, PC; Kibirige, D; Kilonzo, K; Kyazze, AP; Laizer, S; Magombola, D; Mrema, L; Mwayula, IH; Ninsiima, S; Ntinginya, NE; Olomi, W; Romeo, R; Sabi, I; Sharples, K; Te Brake, L; van Crevel, R; van de Maat, J | 1 |
| Falzon, D; Kanchar, A; Masini, T; Mirzayev, F; Viney, K; Yedilbayev, A; Zignol, M | 1 |
| Chang, KC; Huang, SS | 1 |
| Cole, J; Day, CL; Dick, EJ; Foreman, TW; Ganatra, SR; Gandhi, NR; Gonzalez, O; Hall-Ursone, S; Kaushal, D; Mehra, S; Peloquin, CA; Rengarajan, J; Schlesinger, LS; Sharan, R; Shivanna, V; Singh, DK; Thippeshappa, R | 1 |
| Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Langat, D; Mohapi, L; Mwelase, N; Omoz-Oarhe, A; Pham, MM; Podany, AT; Samaneka, W; Supparatpinyo, K; Swindells, S | 1 |
| Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z | 1 |
| Fujita, Y; Huang, HL; Ieiri, I; Lee, CH; Lee, MC; Muraki, S; Wang, JY | 1 |
| Cocoros, NM; Langer, AJ; Nguyen, M; Schmit, KM; Stojanovic, D; Talwar, A; Vonnahme, LA; Walker, WL; Welch, EC | 1 |
| Chaisson, RE; Chihota, V; Churchyard, GJ; Dooley, KE; Jarrett, RT; Marzinke, MA; Shotwell, MS; van der Heijden, Y | 1 |
| Abubakar, I; Bern, H; Booth, HL; Calvert, J; Clarke, AL; Crook, A; Duong, T; Francis, M; Ghanouni, A; Griffiths, C; Hack, V; Hamada, Y; Horne, R; Kunst, H; Layton, C; Lipman, M; Mandelbaum, M; Owen-Powell, E; Rangaka, MX; Sanders, K; Surey, J; White, PJ; Zenner, D | 1 |
| Armstrong, DT; Chaisson, LH; Dowdy, DW; Kamya, MR; Marquez, C; Nangobi, F; Opira, B; Phillips, PPJ; Semitala, FC; Steinmetz, S; Yoon, C | 1 |
| Belknap, R; Borisov, A; Caylà, JA; Chen, MP; Gandhi, NR; Holland, DP; Millet, JP; Moro, RN; Sadowski, C; Scott, NA; Wright, A | 1 |
| Belknap, R; Benedetti, A; Borisov, A; Campbell, JR; Chaisson, RE; Chan, PC; Martinson, N; Menzies, D; Nahid, P; Scott, NA; Sizemore, E; Sterling, TR; Villarino, ME; Wang, JY; Winters, N | 1 |
| Arevalo, B; Beer, K; Belknap, R; Borisov, A; Cayla, JA; Chen, M; Feng, PJ; Holland, DP; Martinson, N; Millet, JP; Miro, JM; Moro, RN; Sadowski, C; Scott, NA; Vernon, A | 1 |
| Amanullah, F; Becerra, MC; Dahri, AA; Farooq, S; Hussain, H; Islam, Z; Jaswal, M; Keshavjee, S; Khan, AJ; Khowaja, S; Madhani, F; Malik, AA; Manzar, S; Noorani, S; Safdar, N; Salahuddin, N; Shah, JA; Shahbaz, SS; Shahzad, M | 1 |
| Chen, X; Feng, Z; Ge, S; Li, R; Li, Y; Miao, Y; Peng, Y; Song, L; Sun, F; Wang, X; Zhang, W; Zhang, Y | 1 |
| Pecora Fulco, P; Taylor, A; Winthrop, E | 1 |
| Adeojo, L; Brooks, KM; Bunn, HT; George, JM; Kovacs, JA; Kumar, P; Pau, AK; Peloquin, CA; Swaim, D | 1 |
25 review(s) available for isoniazid and rifapentine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New approaches to the treatment of latent tuberculosis.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; Mycobacterium tuberculosis; Patient Compliance; Rifampin; Treatment Outcome; Tuberculosis | 2008 |
Pacemaker wire infection with Mycobacterium tuberculosis: a case report and literature review.
Topics: Aged, 80 and over; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Mycobacterium tuberculosis; Pacemaker, Artificial; Recurrence; Rifampin; Surgical Wound Infection; Tomography, X-Ray Computed; Tuberculosis | 2009 |
Treatment of latent infection with Mycobacterium tuberculosis: update 2010.
Topics: Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Communicable Disease Control; Drug Design; Drug Resistance, Bacterial; Female; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Male; Mycobacterium tuberculosis; Patient Compliance; Pyrazinamide; Rifampin; Treatment Outcome | 2011 |
Treatment of latent tuberculosis infection in HIV: shorter or longer?
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Rifampin; Time Factors; Treatment Outcome; Tuberculin Test; Tuberculosis, Multidrug-Resistant | 2012 |
Treatment of latent tuberculosis infection.
Topics: Antitubercular Agents; Disease Progression; Drug Resistance, Bacterial; Drug Therapy, Combination; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Mycobacterium tuberculosis; Rifampin; Tumor Necrosis Factor-alpha | 2013 |
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
Topics: Adult; Antibiotics, Antitubercular; Child; Directly Observed Therapy; Drug Administration Schedule; HIV Seronegativity; Humans; Isoniazid; Latent Tuberculosis; Randomized Controlled Trials as Topic; Rifabutin; Rifampin; Tuberculosis, Pulmonary | 2013 |
Treatment of latent tuberculosis infection.
Topics: Animals; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Rifampin; Time Factors; Tuberculosis | 2013 |
Treatment of latent tuberculosis infection: a network meta-analysis.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Pyrazinamide; Rifampin | 2014 |
Getting it right for children: improving tuberculosis treatment access and new treatment options.
Topics: Antitubercular Agents; BCG Vaccine; Child; Global Health; Health Knowledge, Attitudes, Practice; Humans; Isoniazid; Mycobacterium tuberculosis; Rifampin; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Vaccination | 2015 |
Latent Mycobacterium tuberculosis infection.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Mycobacterium tuberculosis; Practice Guidelines as Topic; Rifampin; Risk Factors | 2015 |
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
Topics: Antirheumatic Agents; Antitubercular Agents; Coinfection; Comorbidity; Disease Management; Drug Users; Emigrants and Immigrants; Evidence-Based Medicine; Health Personnel; HIV Infections; Humans; Ill-Housed Persons; Interferon-gamma Release Tests; Isoniazid; Kidney Failure, Chronic; Latent Tuberculosis; Mass Screening; Practice Guidelines as Topic; Prisoners; Public Health; Radiography, Thoracic; Renal Dialysis; Rifampin; Risk Assessment; Silicosis; Substance-Related Disorders; Transplant Recipients; Tuberculin Test; Tumor Necrosis Factor-alpha; World Health Organization | 2015 |
Improving Treatment Completion Rates for Latent Tuberculosis Infection: A Review of Two Treatment Regimens at a Community Health Center.
Topics: Community Health Centers; Directly Observed Therapy; Drug Therapy, Combination; Hispanic or Latino; Humans; Isoniazid; Latent Tuberculosis; Medication Adherence; Poverty; Rifampin; Wisconsin | 2015 |
Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Male; Network Meta-Analysis; Rifampin; Time Factors | 2017 |
Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model.
Topics: Antitubercular Agents; Bayes Theorem; Comorbidity; Cost-Benefit Analysis; Decision Trees; Emigrants and Immigrants; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Markov Chains; Quality-Adjusted Life Years; Rifampin; Tuberculin Test; United States | 2017 |
A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Incidence; Isoniazid; Latent Tuberculosis; Respiratory Tract Diseases; Rifampin | 2018 |
Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.
Topics: Directly Observed Therapy; Humans; Isoniazid; Latent Tuberculosis; Rifampin; Time Factors; United States | 2018 |
Updates in the Treatment of Active and Latent Tuberculosis.
Topics: Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Mycobacterium tuberculosis; Randomized Controlled Trials as Topic; Rifampin | 2018 |
Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Child; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; HIV Seronegativity; Humans; Isoniazid; Latent Tuberculosis; Rifampin; Tuberculosis, Pulmonary | 2018 |
Treatment for latent tuberculosis infection in low- and middle-income countries: progress and challenges with implementation and scale-up.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Developing Countries; Drug Therapy, Combination; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Rifampin; Young Adult | 2020 |
Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB.
Topics: Anti-HIV Agents; Antitubercular Agents; Drug Interactions; Extensively Drug-Resistant Tuberculosis; HIV Infections; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 2020 |
Adverse events associated with weekly short course isoniazid and rifapentine therapy in pediatric patients with latent tuberculosis: A chart and literature review.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Retrospective Studies; Rifampin; Young Adult | 2021 |
Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Latent Tuberculosis; Medication Adherence; Middle Aged; Rifampin; Young Adult | 2021 |
Targeting Non-Replicating
Topics: Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2021 |
Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Network Meta-Analysis; Rifampin; Tuberculosis | 2023 |
46 trial(s) available for isoniazid and rifapentine
| Article | Year |
|---|---|
[A comparative study of rifapentine treatment and three years follow-up on initial pulmonary tuberculous].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Ethionamide; Female; Follow-Up Studies; Humans; Isoniazid; Male; Middle Aged; Rifampin; Tuberculosis, Pulmonary | 1993 |
Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; Pyrazinamide; Rifampin; Streptomycin; Treatment Outcome; Tuberculosis, Pulmonary | 1998 |
Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Mycobacterium tuberculosis; Recurrence; Rifampin; Time Factors; Tuberculosis, Pulmonary | 1999 |
Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: no activity of isoniazid in the continuation phase.
Topics: Acetylation; Antitubercular Agents; Arylamine N-Acetyltransferase; Drug Therapy, Combination; Genotype; Hong Kong; Humans; Isoniazid; Polymorphism, Restriction Fragment Length; Rifampin; Tuberculosis, Pulmonary | 2000 |
Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Therapy, Combination; Female; Hong Kong; Humans; Isoniazid; Life Tables; Male; Middle Aged; Prognosis; Proportional Hazards Models; Pyrazinamide; Rifampin; Streptomycin; Treatment Outcome; Tuberculosis, Pulmonary | 2002 |
A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.
Topics: Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Isoniazid; Male; Middle Aged; Prospective Studies; Reference Values; Rifampin; Treatment Outcome; Tuberculosis | 2002 |
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.
Topics: Antibiotics, Antitubercular; Drug Administration Schedule; Drug Therapy, Combination; Ethnicity; Female; Humans; Isoniazid; Male; Middle Aged; Radiography, Thoracic; Rifampin; Sputum; Treatment Outcome; Tuberculosis, Pulmonary | 2002 |
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
Topics: Adult; Antibiotics, Antitubercular; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Isoniazid; Male; Middle Aged; Multivariate Analysis; Mycobacterium tuberculosis; Prospective Studies; Rifampin; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary | 2004 |
Recurrent tuberculosis in the United States and Canada: relapse or reinfection?
Topics: Adult; Antitubercular Agents; Canada; Female; Genotype; Humans; Isoniazid; Male; Mycobacterium tuberculosis; Prospective Studies; Recurrence; Rifampin; Tuberculosis, Pulmonary; United States | 2004 |
Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
Topics: Adult; Antitubercular Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Incidence; Isoniazid; Male; Pyrazinamide; Retrospective Studies; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary | 2006 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause of Death; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Isoniazid; Kaplan-Meier Estimate; Male; Mycobacterium tuberculosis; Patient Compliance; Proportional Hazards Models; Rifampin; Risk; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Intention to Treat Analysis; Isoniazid; Male; Middle Aged; Prospective Studies; Rifampin; Risk Factors; Self Administration; Tuberculosis; Virus Latency | 2011 |
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; HIV Seropositivity; Humans; Isoniazid; Kaplan-Meier Estimate; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult | 2014 |
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Rifampin; Treatment Outcome | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Prospective Studies; Respiratory Tract Diseases; Rifampin | 2015 |
Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Male; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; South Africa; Sputum; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult | 2015 |
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Isoniazid; Male; Reverse Transcriptase Inhibitors; Rifampin; RNA, Viral; Tuberculosis | 2015 |
Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
Topics: Adult; Antitubercular Agents; Aspartate Aminotransferases; Brazil; Canada; Case-Control Studies; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Multivariate Analysis; Rifampin; Risk Factors; Spain; United States | 2015 |
Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis.
Topics: Antitubercular Agents; Decision Support Techniques; Ethambutol; Humans; Isoniazid; Markov Chains; Pyrazinamide; Recurrence; Rifampin; Treatment Outcome; Tuberculosis | 2016 |
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
Topics: Adult; Antitubercular Agents; Case-Control Studies; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 2016 |
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Topics: Adolescent; Adult; Americas; Antitubercular Agents; Asia; Child; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Isoniazid; Male; Prospective Studies; Rifampin; Treatment Outcome; Tuberculosis; Young Adult | 2016 |
Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Medication Adherence; Middle Aged; Reminder Systems; Rifampin; Self Administration; Text Messaging | 2017 |
SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Australia; Cost-Benefit Analysis; Disease Eradication; Drug Administration Schedule; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; New Zealand; Prospective Studies; Rifampin; Self Administration; Young Adult | 2017 |
Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials.
Topics: Adolescent; Adult; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infant, Newborn; Isoniazid; Latent Tuberculosis; Middle Aged; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Rifampin; Young Adult | 2018 |
Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Cytokines; Drug Administration Schedule; Drug Interactions; Female; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Rifampin; Young Adult | 2018 |
Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Therapy, Combination; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Mycobacterium tuberculosis; Prospective Studies; Rifampin; Taiwan; Time Factors; Treatment Outcome; Young Adult | 2018 |
Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study.
Topics: Aged; Antibiotics, Antitubercular; China; Communicable Disease Control; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Mycobacterium tuberculosis; Proportional Hazards Models; Rifampin; Risk Factors; Rural Population; Treatment Outcome | 2018 |
Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Ill-Housed Persons; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Mycobacterium tuberculosis; Rifampin; United States | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Male; Medication Adherence; Rifampin; Tuberculosis | 2019 |
Preventive tuberculosis treatment effect on QuantiFERON TB-Gold in-tube testing in a high tuberculosis-endemic country: A clinical trial.
Topics: Antigens, Bacterial; Antitubercular Agents; China; Diagnostic Tests, Routine; Endemic Diseases; Female; Follow-Up Studies; Humans; Interferon-gamma; Interferon-gamma Release Tests; Isoniazid; Male; Middle Aged; Prospective Studies; Rifampin; Tuberculin Test; Tuberculosis | 2020 |
Dynamic changes of interferon gamma release assay results with latent tuberculosis infection treatment.
Topics: Antitubercular Agents; Biomarkers; China; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Interferon-gamma; Interferon-gamma Release Tests; Isoniazid; Latent Tuberculosis; Male; Rifampin; Treatment Outcome | 2020 |
Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.
Topics: Adult; Drug Administration Schedule; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Isoniazid; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Rifampin; South Africa; Treatment Outcome; Tuberculosis; Viral Load | 2020 |
Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Drug Administration Schedule; Drug Interactions; Female; Healthy Volunteers; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Prospective Studies; Pyridones; Reverse Transcriptase Inhibitors; Rifampin; Triazoles; Tuberculosis; Young Adult | 2020 |
Efficacy and safety of weekly rifapentine and isoniazid for tuberculosis prevention in Chinese silicosis patients: a randomized controlled trial.
Topics: Antitubercular Agents; Area Under Curve; China; Drug Administration Schedule; Half-Life; Humans; Isoniazid; Male; Medication Adherence; Middle Aged; Rifampin; Silicosis; Tuberculosis, Pulmonary | 2021 |
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Arylamine N-Acetyltransferase; Benzoxazines; Cyclopropanes; Drug Synergism; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Nevirapine; Pharmacogenetics; Rifampin; Young Adult | 2021 |
Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Nevirapine; Rifampin; Young Adult | 2021 |
An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Isoniazid; Latent Tuberculosis; London; Male; Middle Aged; Pilot Projects; Rifampin; Self Administration; Treatment Outcome; Young Adult | 2021 |
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.
Topics: Adult; Antitubercular Agents; Biomarkers; Drug Administration Schedule; Female; HIV Seronegativity; Humans; Incidence; Isoniazid; Male; Mycobacterium tuberculosis; Reverse Transcriptase Polymerase Chain Reaction; Rifampin; RNA, Bacterial; South Africa; Treatment Outcome; Tuberculosis; Young Adult | 2021 |
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.
Topics: Adult; Antitubercular Agents; Child; Drug Therapy, Combination; Female; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Male; Pregnancy; Pregnant Women; Rifampin; Tuberculosis | 2022 |
Annual Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized Trial.
Topics: Adolescent; Adult; Anti-HIV Agents; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethiopia; Female; HIV Infections; Humans; Isoniazid; Male; Mozambique; Rifampin; South Africa; Tuberculosis, Pulmonary; Young Adult | 2021 |
Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Therapy, Combination; Female; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Rifampin; Tuberculosis; Uganda | 2021 |
Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial.
Topics: Adult; Antitubercular Agents; Cohort Studies; Diabetes Mellitus, Type 2; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Randomized Controlled Trials as Topic; Rifampin; Tanzania | 2022 |
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Topics: Antitubercular Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Moxifloxacin; Rifampin; Tuberculosis; Tuberculosis, Pulmonary | 2023 |
Evaluating the effect of short-course rifapentine-based regimens with or without enhanced behaviour-targeted treatment support on adherence and completion of treatment for latent tuberculosis infection among adults in the UK (RID-TB: Treat): protocol for
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Rifampin; State Medicine; United Kingdom; Young Adult | 2022 |
Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Self Report; United States | 2023 |
Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial.
Topics: Clinical Trials, Phase II as Topic; Humans; Isoniazid; Moxifloxacin; Multicenter Studies as Topic; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis | 2023 |
110 other study(ies) available for isoniazid and rifapentine
| Article | Year |
|---|---|
Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.
Topics: Animals; Antitubercular Agents; Biological Availability; Interferon-gamma; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyridones; Quinolones; Treatment Outcome; Tuberculosis, Pulmonary | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Activity of intermittently administered rifampicin and cyclopentyl rifamycin (or DL473) on experimental tuberculosis in the mouse].
Topics: Animals; DNA-Directed RNA Polymerases; Drug Therapy, Combination; Female; Isoniazid; Mice; Pyrazinamide; Rifampin; Streptomycin; Tuberculosis | 1983 |
Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Dose-Response Relationship, Drug; Isoniazid; Mice; Microbial Sensitivity Tests; Rifampin; Tuberculosis | 1981 |
Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice.
Topics: Animals; Antitubercular Agents; Colony-Forming Units Assay; Drug Therapy, Combination; Female; Immunity; Isoniazid; Mice; Mice, Nude; Pyrazinamide; Rifampin; Tuberculosis | 1994 |
Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Female; Isoniazid; Mice; Mycobacterium tuberculosis; Rifampin; Stem Cells; Tuberculosis | 1999 |
Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Isoniazid; Mice; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Rifamycins; Tuberculosis | 1999 |
Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Ethambutol; Female; Isoniazid; Lung; Mice; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Spleen; Streptomycin; Tuberculosis | 2000 |
Tuberculosis treatment: dangerous regimens?
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Thioacetazone; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; World Health Organization | 2001 |
Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Resistance, Microbial; Female; Fluoroquinolones; Isoniazid; Lung; Mice; Moxifloxacin; Mycobacterium tuberculosis; Organ Size; Quinolines; Rifampin; Spleen; Streptomycin; Survival Rate; Tuberculosis | 2001 |
Another step on the path to better TB therapies.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Hong Kong; Humans; Isoniazid; Prognosis; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis, Pulmonary | 2002 |
In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Drug Combinations; Fluoroquinolones; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin | 2004 |
Rifapentine for the treatment of tuberculosis: is it all it can be?
Topics: Antibiotics, Antitubercular; Dose-Response Relationship, Drug; Drug Combinations; Half-Life; Humans; Isoniazid; Rifampin; Tuberculosis, Pulmonary | 2004 |
Monitoring the ingestion of anti-tuberculosis drugs by simple non-invasive methods.
Topics: Antitubercular Agents; Drug Monitoring; Humans; Isoniazid; Isonicotinic Acids; Microbial Sensitivity Tests; Patient Compliance; Reproducibility of Results; Retrospective Studies; Rifampin; Self Administration; Staphylococcus aureus | 2006 |
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Pyrazinamide; Quinolines; Rifampin; Tuberculosis, Pulmonary | 2006 |
Study of the interaction between rifapentine and isoniazid under acid conditions.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Drug Interactions; Hydrogen-Ion Concentration; Isoniazid; Rifampin | 2006 |
Short-course regimens for latent tuberculosis: what is ready for prime time?
Topics: Antitubercular Agents; Humans; Isoniazid; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis; Virus Latency | 2007 |
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Fluoroquinolones; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Secondary Prevention; Time Factors; Tuberculosis | 2007 |
Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis.
Topics: Animals; Antigens, Bacterial; Antitubercular Agents; BCG Vaccine; Female; Guinea Pigs; Humans; Interferon-gamma; Isoniazid; Liposomes; Mice; Mice, Inbred C57BL; Mycobacterium tuberculosis; Rifampin; Specific Pathogen-Free Organisms; T-Lymphocytes; Time Factors; Treatment Outcome; Tuberculosis Vaccines; Tuberculosis, Pulmonary | 2008 |
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Pyrazinamide; Quinolines; Recurrence; Rifampin; Time Factors; Treatment Outcome; Tuberculosis | 2008 |
Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; Markov Chains; Rifampin; Tuberculosis | 2009 |
Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
Topics: Animals; Anti-Inflammatory Agents; Antibiotics, Antitubercular; Antitubercular Agents; Cortisone; Disease Models, Animal; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Mice, Nude; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Secondary Prevention; Time Factors; Tuberculosis, Pulmonary | 2011 |
What is thwarting tuberculosis prevention in high-burden settings?
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Infant; Infant, Newborn; Isoniazid; Rifampin; Tuberculosis | 2011 |
Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Drug Administration Schedule; Humans; Isoniazid; Latent Tuberculosis; Models, Biological; Patient Compliance; Rifampin; Self Administration; United States | 2011 |
Practical preventive therapy for tuberculosis?
Topics: Antitubercular Agents; Humans; Isoniazid; Male; Rifampin; Tuberculosis | 2011 |
Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.
Topics: Adult; Antitubercular Agents; Child; Child, Preschool; Contraindications; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Isoniazid; Latent Tuberculosis; Randomized Controlled Trials as Topic; Rifampin | 2011 |
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2012 |
Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.
Topics: Animals; Antitubercular Agents; Female; Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis | 2012 |
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Isoniazid; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide; Random Allocation; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary | 2012 |
Transmission of Mycobacterium tuberculosis in a High School and School-Based Supervision of an Isoniazid-Rifapentine Regimen for Preventing Tuberculosis - Colorado, 2011-2012.
Topics: Antitubercular Agents; Capacity Building; Colorado; Communication; Community-Institutional Relations; Contact Tracing; Drug Therapy, Combination; Humans; Isoniazid; Mycobacterium tuberculosis; Rifampin; School Health Services; Tuberculosis | 2013 |
Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates.
Topics: Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Directly Observed Therapy; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Organ Transplantation; Prospective Studies; Rifampin | 2014 |
Cost-effectiveness of treating latent tuberculous infection: a step towards elimination?
Topics: Antitubercular Agents; Drug Costs; Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2013 |
Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
Topics: Antitubercular Agents; Computer Simulation; Cost-Benefit Analysis; Directly Observed Therapy; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Hospital Costs; Humans; Isoniazid; Latent Tuberculosis; Models, Economic; Quality-Adjusted Life Years; Rifampin; Time Factors; Treatment Outcome; United States | 2013 |
Twelve-dose drug regimen now also an option for preventing tuberculosis in children and adolescents.
Topics: Antitubercular Agents; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Rifampin | 2015 |
Tuberculosis of the cervical spine.
Topics: Adult; Antibiotics, Antitubercular; Cervical Vertebrae; Drug Therapy, Combination; Humans; Isoniazid; Magnetic Resonance Imaging; Male; Neurosurgical Procedures; Orthopedic Procedures; Radiography; Rifampin; Tomography, X-Ray Computed; Treatment Outcome; Tuberculosis, Spinal | 2015 |
Treatment for Tuberculosis Infection With 3 Months of Isoniazid and Rifapentine in New York City Health Department Clinics.
Topics: Adult; Ambulatory Care Facilities; Antitubercular Agents; Directly Observed Therapy; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; New York City; Patient Compliance; Public Health; Rifampin; Young Adult | 2016 |
Uniform and amorphous rifampicin microspheres obtained by freezing induced LLPS during lyophilization.
Topics: Administration, Inhalation; Cell Line; Chemistry, Pharmaceutical; Drug Carriers; Dynamic Light Scattering; Freeze Drying; Humans; Isoniazid; Macrophages; Microscopy, Electron, Scanning; Microspheres; Paclitaxel; Particle Size; Phagocytosis; Rifampin; Solubility; tert-Butyl Alcohol; Water; X-Ray Diffraction | 2015 |
Childhood tuberculosis in the United States: shifting the focus to prevention.
Topics: Antibiotics, Antitubercular; Child; Humans; Incidence; Interferon-gamma Release Tests; Isoniazid; Mass Screening; Rifampin; Tuberculosis; United States | 2015 |
School-based Study to Identify and Treat Adolescent Students at Risk for Tuberculosis Infection.
Topics: Adolescent; Antitubercular Agents; Directly Observed Therapy; Drug Combinations; Female; Humans; Isoniazid; Male; Mass Screening; Mycobacterium tuberculosis; Poverty; Rifampin; Risk Factors; School Health Services; Students; Surveys and Questionnaires; Texas; Tuberculin Test; Tuberculosis | 2016 |
Safety and Adherence for 12 Weekly Doses of Isoniazid and Rifapentine for Pediatric Tuberculosis Infection.
Topics: Adolescent; Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Isoniazid; Male; Medication Adherence; Rifampin; Skin Tests; Treatment Outcome; Tuberculosis; Tuberculosis, Pulmonary; Young Adult | 2016 |
[Determination of in vitro synergy by a checkerboard method when 3 core antimicrobial agents of the retreatment new scheme combined against MDR-MTB and XDR-MTB].
Topics: Aminosalicylic Acids; Antibiotics, Antitubercular; Drug Synergism; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Retreatment; Rifabutin; Rifampin; Tuberculosis, Multidrug-Resistant | 2016 |
Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
Topics: Adult; Aged; Antitubercular Agents; Biomarkers; Chemical and Drug Induced Liver Injury; Choice Behavior; Drug Therapy, Combination; Female; Humans; Isoniazid; Kidney Diseases; Kidney Transplantation; Latent Tuberculosis; Male; Medication Adherence; Middle Aged; Reminder Systems; Retrospective Studies; Rifampin; Time Factors; Transaminases; Treatment Outcome; Treatment Refusal; Up-Regulation; Waiting Lists | 2017 |
Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cost-Benefit Analysis; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Medication Adherence; Middle Aged; Pilot Projects; Rifampin; Taiwan; Time Factors; Tuberculosis, Pulmonary; Young Adult | 2016 |
Severe hypertension after initiation of rifapentine/isoniazid for latent tuberculosis in renal transplant candidates.
Topics: Adult; Aged; Antitubercular Agents; Blood Pressure; Cohort Studies; Drug Therapy, Combination; Humans; Hypertension; Isoniazid; Kidney Transplantation; Latent Tuberculosis; Middle Aged; Rifampin; Time Factors; Transplant Recipients | 2017 |
Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.
Topics: Adult; Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Patient Compliance; Retrospective Studies; Rifampin; United States; Washington | 2017 |
The tuberculosis taboo.
Topics: Antitubercular Agents; Contact Tracing; Drug Therapy, Combination; Global Health; Humans; Isoniazid; Latent Tuberculosis; Rifampin; Taboo; Time Factors; Tuberculosis; World Health Organization | 2017 |
Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates.
Topics: Adult; Aged; Antibiotics, Antitubercular; Directly Observed Therapy; Drug Therapy, Combination; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; New York; Rifampin | 2017 |
Use of Video Directly Observed Therapy for Treatment of Latent Tuberculosis Infection - Johnson County, Kansas, 2015.
Topics: Antitubercular Agents; Contact Tracing; Directly Observed Therapy; Humans; Isoniazid; Kansas; Latent Tuberculosis; Mycobacterium tuberculosis; Patient Compliance; Rifampin; Schools; Telemedicine; Treatment Outcome; Videoconferencing | 2017 |
High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ill-Housed Persons; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Mycobacterium tuberculosis; Rifampin; Students; United States; Young Adult | 2017 |
Silicotuberculosis with oesophagobronchial fistulas and broncholithiasis: a case report.
Topics: Aged; Antibiotics, Antitubercular; Bronchial Fistula; Esophageal Fistula; Esophagoscopy; Female; Humans; Isoniazid; Lithiasis; Pyrazinamide; Rifampin; Silicotuberculosis; Stents; Treatment Outcome | 2018 |
NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Fibrosis; Foam Cells; Humans; Hypoxia; Isoniazid; Mice; Mice, Knockout; Necrosis; Nitric Oxide Synthase Type II; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary | 2017 |
Use of Rifapentine and Isoniazid Directly Observed Therapy for the Treatment of Latent Tuberculosis Infection in a Military Clinic.
Topics: Adolescent; Adult; Ambulatory Care Facilities; Antitubercular Agents; Directly Observed Therapy; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Military Personnel; Retrospective Studies; Rifampin; United States | 2017 |
Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center.
Topics: Adult; Antitubercular Agents; Disease Management; Drug Therapy, Combination; Female; Health Personnel; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Retrospective Studies; Rifampin | 2017 |
Completion Rate and Safety of Tuberculosis Infection Treatment With Shorter Regimens.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infant; Infant, Newborn; Isoniazid; Male; Medication Adherence; Retrospective Studies; Rifampin; Texas; Tuberculosis | 2018 |
Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
Topics: Anti-HIV Agents; Antitubercular Agents; Cost-Benefit Analysis; Drug Therapy, Combination; HIV Infections; Humans; Isoniazid; Markov Chains; Rifampin; Tuberculosis | 2018 |
Three months of once-weekly isoniazid plus rifapentine (3HP) in treating latent tuberculosis infection is feasible in patients with rheumatoid arthritis.
Topics: Aged; Antitubercular Agents; Arthritis, Rheumatoid; Drug Administration Schedule; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Rifampin | 2018 |
National position statement for the management of latent tuberculosis infection.
Topics: Antitubercular Agents; Australia; Chemoprevention; Communicable Disease Control; Disease Notification; Drug Combinations; Emigration and Immigration; Humans; Interferon-gamma Release Tests; Isoniazid; Latent Tuberculosis; Mycobacterium tuberculosis; Prevalence; Rifampin; Transients and Migrants; Tuberculin Test; Tuberculosis, Pulmonary | 2017 |
Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoniazid; Kidney Failure, Chronic; Latent Tuberculosis; Male; Middle Aged; Renal Dialysis; Rifampin; Safety | 2019 |
Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.
Topics: Adolescent; Antibiotics, Antitubercular; Centers for Disease Control and Prevention, U.S.; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Mycobacterium tuberculosis; Rifampin; United States | 2018 |
Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study.
Topics: Adolescent; Adult; Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Liberation; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Nitroimidazoles; Oxazoles; Proof of Concept Study; Rifampin; Treatment Outcome; Young Adult | 2018 |
Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Female; Health Care Costs; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Rifampin; Young Adult | 2019 |
Treatment of latent tuberculosis with 12 weeks isoniazid/rifapentine in clinical practice.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Retrospective Studies; Rifampin; Risk; Treatment Outcome; Young Adult | 2019 |
Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Child, Preschool; Female; Humans; Incidence; Isoniazid; Latent Tuberculosis; Male; Medication Adherence; Middle Aged; Norway; Prospective Studies; Rifampin; Young Adult | 2018 |
Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study.
Topics: Adult; Ambulatory Care Facilities; Antitubercular Agents; Data Collection; Directly Observed Therapy; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Rifampin; Telemedicine; Videoconferencing; Young Adult | 2018 |
New short regimens for latent tuberculosis treatment: safety first!
Topics: Aged; Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2018 |
Ending Tuberculosis through Prevention.
Topics: HIV; Humans; Isoniazid; Rifampin; Tuberculosis | 2019 |
Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly.
Topics: Aged; Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2019 |
Outlook for tuberculosis elimination in California: An individual-based stochastic model.
Topics: Algorithms; Antitubercular Agents; Calibration; California; Computer Simulation; Cost-Benefit Analysis; Disease Eradication; Epidemics; Humans; Incidence; Isoniazid; Mass Screening; Quality-Adjusted Life Years; Rifampin; Risk Factors; Stochastic Processes; Tuberculin Test; Tuberculosis; World Health Organization | 2019 |
Latent tuberculosis treatment completion rates from prescription drug administrative data.
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Child; Child, Preschool; Databases, Factual; Female; Humans; Infant; Infant, Newborn; Isoniazid; Latent Tuberculosis; Male; Manitoba; Middle Aged; Prescription Drugs; Rifampin; Treatment Adherence and Compliance; Young Adult | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: HIV; Humans; Isoniazid; Rifampin; Tuberculosis | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Reply.
Topics: HIV; Humans; Isoniazid; Rifampin; Tuberculosis | 2019 |
Isoniazid and Rifapentine Treatment Eradicates Persistent
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Latent Tuberculosis; Macaca; Models, Animal; Mycobacterium tuberculosis; Rifampin; Treatment Outcome; Tuberculosis | 2020 |
Nonparticipation reasons in a randomized international trial of a new latent tuberculosis infection regimen.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Patient Selection; Randomized Controlled Trials as Topic; Refusal to Participate; Rifampin; Risk Factors; Young Adult | 2020 |
Modeling Treatment of Latent Tuberculosis: Shortening the Leap of Faith?
Topics: Animals; Isoniazid; Latent Tuberculosis; Macaca; Mycobacterium tuberculosis; Rifampin | 2020 |
Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Odds Ratio; Polymorphism, Single Nucleotide; Rifampin | 2019 |
Addressing Latent Tuberculosis Infection Treatment Through a Collaborative Care Model With Community Pharmacies and a Health Department.
Topics: Adult; Antibiotics, Antitubercular; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; New Mexico; Pharmacies; Pilot Projects; Prospective Studies; Public Health; Rifampin | 2020 |
Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries.
Topics: Antitubercular Agents; China; Humans; Incidence; Interferon-gamma Release Tests; Isoniazid; Latent Tuberculosis; Prevalence; Rifampin; Rural Population; Tuberculin Test; Tumor Necrosis Factor-alpha | 2020 |
Cost-effectiveness of IGRA/QFT-Plus for TB screening of migrants in Oman.
Topics: Cost-Benefit Analysis; Female; Humans; Interferon-gamma Release Tests; Isoniazid; Latent Tuberculosis; Markov Chains; Mass Screening; Oman; Quality-Adjusted Life Years; Rifampin; Transients and Migrants; Tuberculosis | 2020 |
Analysis of Severe Adverse Events Reported Among Patients Receiving Isoniazid-Rifapentine Treatment for Latent Mycobacterium tuberculosis Infection-United States, 2012-2016.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Mycobacterium tuberculosis; Rifampin; United States | 2020 |
Prevention of tuberculosis in HIV infection with novel drugs.
Topics: Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Isoniazid; Oxazines; Piperazines; Pyridones; Rifampin; Tuberculosis | 2020 |
Safety and treatment completion of latent tuberculosis infection treatment in the elderly population-A prospective observational study in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Incidence; Isoniazid; Kidney Failure, Chronic; Latent Tuberculosis; Male; Middle Aged; Prospective Studies; Rifampin; Taiwan | 2020 |
Simplifying Rifapentine Dosing for Tuberculosis Treatment and Prevention.
Topics: Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2020 |
Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2021 |
Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Isoniazid; Latent Tuberculosis; Middle Aged; Retrospective Studies; Rifampin; United States | 2021 |
Estimated Population-Level Impact of Using a Six-Week Regimen of Daily Rifapentine to Treat Latent Tuberculosis Infection in the United States.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Rifampin; United States | 2020 |
Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
Topics: Anti-HIV Agents; Antitubercular Agents; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Male; Quality-Adjusted Life Years; Rifampin; Tuberculosis; Uganda | 2020 |
Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection.
Topics: Aged; Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Middle Aged; Rifampin | 2021 |
Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Rifampin; Tuberculosis | 2021 |
Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda.
Topics: Adult; Decision Making; Directly Observed Therapy; Female; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Patient Preference; Random Allocation; Rifampin; Self Administration; Self Efficacy; Uganda | 2021 |
Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Cohort Studies; Duration of Therapy; Female; Humans; Isoniazid; Male; Pakistan; Prospective Studies; Rifampin; Treatment Adherence and Compliance; Tuberculosis; Young Adult | 2021 |
Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting.
Topics: Antitubercular Agents; Canada; Cost-Benefit Analysis; Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2021 |
High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection-A single center study.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; China; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infant; Isoniazid; Latent Tuberculosis; Male; Medication Adherence; Rifampin | 2021 |
Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Latent Tuberculosis; Mice; Rifampin | 2021 |
Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Piperazines; Pyridones; Rifampin; Tenofovir | 2021 |
Tuberculosis Infection in Children and Adolescents: Testing and Treatment.
Topics: Adolescent; Age Factors; Antitubercular Agents; BCG Vaccine; Child; Child, Preschool; Cross Reactions; False Positive Reactions; Humans; Immunocompromised Host; Infant; Interferon-gamma Release Tests; Isoniazid; Latent Tuberculosis; Mycobacterium bovis; Mycobacterium tuberculosis; Nontuberculous Mycobacteria; Rifampin; Sensitivity and Specificity; Tuberculin Test | 2021 |
Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection.
Topics: Antitubercular Agents; Drug Interactions; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2022 |
Whole-Blood 3-Gene Signature as a Decision Aid for Rifapentine-based Tuberculosis Preventive Therapy.
Topics: Antitubercular Agents; Decision Support Techniques; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2022 |
Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
Topics: Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis, Pulmonary; United States | 2022 |
Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally.
Topics: Europe; Humans; Isoniazid; Rifampin; Tuberculosis | 2022 |
How Flu-like Syndromes Contribute to Termination of Weekly Rifapentine-Based TB Preventive Therapy Is Still Poorly Predictable.
Topics: Humans; Isoniazid; Rifampin; Syndrome | 2022 |
Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs.
Topics: Animals; Antitubercular Agents; Isoniazid; Latent Tuberculosis; Lung; Macaca mulatta; Mycobacterium tuberculosis; Positron Emission Tomography Computed Tomography; Rifampin; Tuberculosis | 2022 |
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Isoniazid; Nevirapine; Rifampin | 2022 |
Isoniazid level and flu-like symptoms during rifapentine-based tuberculosis preventive therapy: A population pharmacokinetic analysis.
Topics: Antitubercular Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Isoniazid; Latent Tuberculosis; Prospective Studies | 2023 |
Using the Food and Drug Administration´s Sentinel System for surveillance of TB infection.
Topics: Antitubercular Agents; Drug Prescriptions; Humans; Isoniazid; Rifampin; Tuberculosis; United States; United States Food and Drug Administration | 2022 |
High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Body Weight; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Latent Tuberculosis | 2023 |
Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3 months weekly isoniazid-rifapentine.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Male; Uganda; Viremia | 2023 |
Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection.
Topics: Antitubercular Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoniazid; Latent Tuberculosis; Middle Aged | 2023 |
Scale-Up of Rifapentine and Isoniazid for Tuberculosis Prevention Among Household Contacts in 2 Urban Centers: An Effectiveness Assessment.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Male; Tuberculosis | 2023 |
Alternative dolutegravir dosing strategies with concurrent rifapentine utilized for latent tuberculosis treatment.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Middle Aged; Rifampin | 2023 |
Pharmacokinetics, Safety, and Tolerability of Once-Daily Darunavir With Cobicistat and Weekly Isoniazid/Rifapentine.
Topics: Cobicistat; Cross-Over Studies; Darunavir; Drug Combinations; HIV Infections; Humans; Isoniazid | 2023 |